These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 21642685)

  • 21. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
    Gao J; Dang Y; Sun N; Li J; Shen L
    Med Oncol; 2012 Dec; 29(5):3039-45. PubMed ID: 22815156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol.
    Hirai I; Tanese K; Fukuda K; Fusumae T; Nakamura Y; Sato Y; Amagai M; Funakoshi T
    Medicine (Baltimore); 2021 Dec; 100(49):e27832. PubMed ID: 34889232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.
    Cho JH; Kim KM; Kwon M; Kim JH; Lee J
    Invest New Drugs; 2012 Oct; 30(5):2008-14. PubMed ID: 22068222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb.
    Yamaguchi M; Harada K; Ando N; Kawamura T; Shibagaki N; Shimada S
    Clin Exp Dermatol; 2011 Mar; 36(2):174-7. PubMed ID: 20545949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
    Guo J; Carvajal RD; Dummer R; Hauschild A; Daud A; Bastian BC; Markovic SN; Queirolo P; Arance A; Berking C; Camargo V; Herchenhorn D; Petrella TM; Schadendorf D; Sharfman W; Testori A; Novick S; Hertle S; Nourry C; Chen Q; Hodi FS
    Ann Oncol; 2017 Jun; 28(6):1380-1387. PubMed ID: 28327988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting.
    Tay CM; Ong CW; Lee VK; Pang B
    Pathology; 2013 Feb; 45(2):127-37. PubMed ID: 23277171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
    Lee SJ; Kim TM; Kim YJ; Jang KT; Lee HJ; Lee SN; Ahn MS; Hwang IG; Lee S; Lee MH; Lee J
    Oncologist; 2015 Nov; 20(11):1312-9. PubMed ID: 26424760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic implications of KIT in melanoma.
    Postow MA; Carvajal RD
    Cancer J; 2012; 18(2):137-41. PubMed ID: 22453014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Another option in our KIT of effective therapies for advanced melanoma.
    Carvajal RD
    J Clin Oncol; 2013 Sep; 31(26):3173-5. PubMed ID: 23940226
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
    Larkin J; Marais R; Porta N; Gonzalez de Castro D; Parsons L; Messiou C; Stamp G; Thompson L; Edmonds K; Sarker S; Banerji J; Lorigan P; Evans TRJ; Corrie P; Marshall E; Middleton MR; Nathan P; Nicholson S; Ottensmeier C; Plummer R; Bliss J; Valpione S; Turajlic S
    Cell Rep Med; 2024 Mar; 5(3):101435. PubMed ID: 38417447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
    Delyon J; Chevret S; Jouary T; Dalac S; Dalle S; Guillot B; Arnault JP; Avril MF; Bedane C; Bens G; Pham-Ledard A; Mansard S; Grange F; Machet L; Meyer N; Legoupil D; Saiag P; Idir Z; Renault V; Deleuze JF; Hindie E; Battistella M; Dumaz N; Mourah S; Lebbe C;
    J Invest Dermatol; 2018 Jan; 138(1):58-67. PubMed ID: 28843487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
    Todd JR; Becker TM; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
    Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
    JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
    Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
    Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
    Smalley KS; Sondak VK; Weber JS
    Histol Histopathol; 2009 May; 24(5):643-50. PubMed ID: 19283671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.